Active, not recruiting
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788
- Conditions
- Abnormalities, Multiple, Angiomatosis, Cardiovascular Diseases, +14 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- University of Michigan Ann Arbor, Michigan, United States
- University of Pennsylvania Medical Center Philadelphia, Pennsylvania, United States